(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.06%) $78.11
(5.50%) $2.15
(0.03%) $2 310.40
(-0.12%) $26.80
(0.26%) $965.15
(-0.35%) $0.929
(-1.14%) $10.87
(-0.14%) $0.797
(0.35%) $91.45
8.33% £ 58.50
Live Chart Being Loaded With Signals
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom...
Stats | |
---|---|
Volumen de hoy | 297 128 |
Volumen promedio | 184 066 |
Capitalización de mercado | 0.00 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -0.110 |
ATR14 | £0 (0.00%) |
Tiziana Life Sciences PLC Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Tiziana Life Sciences PLC Finanzas
Annual | 2020 |
Ingresos: | £0.00 |
Beneficio Bruto: | £0.00 (0.00 %) |
EPS: | £-0.191 |
FY | 2020 |
Ingresos: | £0.00 |
Beneficio Bruto: | £0.00 (0.00 %) |
EPS: | £-0.191 |
FY | 2019 |
Ingresos: | £0.00 |
Beneficio Bruto: | £0.00 (0.00 %) |
EPS: | £-0.0540 |
FY | 2018 |
Ingresos: | £0.00 |
Beneficio Bruto: | £0.00 (0.00 %) |
EPS: | £-0.0940 |
Financial Reports:
No articles found.
Tiziana Life Sciences PLC
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico